Safety and efficacy of human albumin solution with restored structural profile in decompensated cirrhosis

Phase 2, randomised trial of albumin (human) in Cirrhosis, decompensated cirrhosis and Ascites in cirrhosis (2 arms), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoints: Effective albumin concentration over time at 6 months and Safety of restored structural profile human albumin solution up to 6 months. Planned start Oct 2024; status: authorised.